Hybrigenics develops new oral formulations of inecalcitol
Hybrigenics seeks patent protection until 2030 for innovative oral formulations optimized for the delivery of high doses of inecalcitol
All microdosed vitamin D analogues are currently marketed as oily solutions in soft gelatin capsules. The first formulations of inecalcitol were also soft gel capsules of different increasing concentrations and strengths, up to a maximum of 1 mg unit dose. The patients treated at the highest tolerated dose had to swallow four such relatively big capsules. The new capsules are more concentrated in inecalcitol and contain a fixed 2 mg amount. Treatment will therefore be more convenient with a maximum of two small capsules to swallow, favoring compliance.
Pharmaceutical stability and human bioavailability studies in healthy volunteers are ongoing. The objective is to start Phase IIb efficacy clinical trials in hormone-refractory prostate cancer and severe psoriasis with an already optimized formulation suitable for future commercialization.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.